Soleo Health will distribute Leqembi, the newly approved Alzheimer's therapy, to provider offices and infusion centers, as well as administer it across its own ambulatory infusions centers.
Soleo Health has been selected by Eisai as the sole specialty pharmacy distribution partner for Leqembi (lecanemab-irmb) to treat patients with Alzheimer’s disease. Leqembi is an anti-amyloid monoclonal antibody used to treat patients with mild cognitive impairment and mild Alzheimer’s disease. The FDA granted accelerated approval to the therapy on Jan. 6, 2023.
Patients will be supported through Soleo Health’s Alzheimer’s Disease Therapeutic Care Management Center, which is staffed with interdisciplinary teams comprising experienced physician specialists, nurse practitioners, therapy-care pharmacists, registered nurses, reimbursement specialists and patient care ambassadors. Soleo Health has locations nationwide with pharmacy licensure in all 50 states.
Soleo Health will distribute Leqembi to provider offices and infusion centers, as well as administer it across its own ambulatory infusions centers, including those owned and operated through its provider division, Virtis Health.
Eisai and its partner Biogen have submitted a supplemental BLA seeking full approval for Leqembi based on data from the phase 3 confirmatory trial Clarity AD.